We are live on ! Find out more
AA

AlphaCentric Advisors Portfolio holdings

AUM $100M
This Fund
S&P 500
This Quarter Est. Return
-6.52%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$97.4M
AUM Growth
–
Cap. Flow
+$112M
Cap. Flow %
114.43%
Top 10 Hldgs %
32.96%
Holding
184
New
184
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
SHY icon
iShares 1-3 Year Treasury Bond ETF
SHY
+$12.9M
2
RITM icon
Rithm Capital
RITM
+$4.16M
3
GSK icon
GSK
GSK
+$2.65M
4
SNY icon
Sanofi
SNY
+$2.47M
5
PETQ
PetIQ, Inc. Class A Common Stock
PETQ
+$2.41M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 43.93%
2 Real Estate 12%
3 Financials 8.32%
4 Technology 3.45%
5 Industrials 3.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NLY icon
51
Annaly Capital Management
NLY
$16.9B
$644K 0.66%
+37,500
New +$945K
BTAI icon
52
BioXcel Therapeutics
BTAI
$27.4M
$591K 0.61%
+3,125
New +$726K
KNSA icon
53
Kiniksa Pharmaceuticals
KNSA
$4.92B
$552K 0.57%
+43,000
New +$490K
AMRN
54
Amarin Corp
AMRN
$292M
$545K 0.56%
+25,000
New +$671K
CHRS icon
55
Coherus Oncology
CHRS
$216M
$509K 0.52%
+53,000
New +$536K
NUVB icon
56
Nuvation Bio
NUVB
$2.02B
$482K 0.49%
+215,000
New +$614K
CLDX icon
57
Celldex Therapeutics
CLDX
$2.77B
$478K 0.49%
+17,000
New +$521K
MBOT icon
58
Microbot Medical
MBOT
$118M
$478K 0.49%
+100,000
New +$514K
UTHR icon
59
United Therapeutics
UTHR
$22.7B
$471K 0.48%
+2,250
New +$503K
SAFE
60
Safehold
SAFE
$1.22B
$469K 0.48%
+10,399
New +$722K
JAZZ icon
61
Jazz Pharmaceuticals
JAZZ
$15.5B
$467K 0.48%
+3,500
New +$532K
MORF
62
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$453K 0.46%
+16,000
New +$446K
KSCP icon
63
Knightscope
KSCP
$25.4M
$436K 0.45%
+3,600
New +$524K
AGIO icon
64
Agios Pharmaceuticals
AGIO
$2.36B
$424K 0.44%
+15,000
New +$402K
VRNA
65
DELISTED
Verona Pharma
VRNA
$409K 0.42%
+40,000
New +$337K
NUE icon
66
Nucor
NUE
$53.9B
$400K 0.41%
+3,737
New +$469K
AMYT
67
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$388K 0.4%
+56,000
New +$418K
DVAX
68
DELISTED
Dynavax Technologies
DVAX
$376K 0.39%
+36,000
New +$469K
CTMX icon
69
CytomX Therapeutics
CTMX
$788M
$373K 0.38%
+257,500
New +$396K
LEN icon
70
Lennar Class A
LEN
$20.2B
$363K 0.37%
+5,028
New +$391K
MMD
71
MainStay MacKay DefinedTerm Municipal Opportunities Fund
MMD
$288M
$351K 0.36%
+22,500
New +$406K
LHDX
72
DELISTED
Lucira Health, Inc. Common Stock
LHDX
$339K 0.35%
+320,200
New +$729K
AUR icon
73
Aurora
AUR
$11.9B
$332K 0.34%
+150,000
New +$371K
AGNC icon
74
AGNC Investment
AGNC
$12.9B
$325K 0.33%
+38,596
New +$453K
FANG icon
75
Diamondback Energy
FANG
$55B
$305K 0.31%
+2,535
New +$316K
1 2
3
4 5

Similar funds

WCM
Weber Capital Management San Francisco, California $100M AUM
FCM
Fourier Capital Management Hong Kong $100M AUM
BIA
Baer Investment Advisory Corte Madera, California $100M AUM 23.87% 1-Year Est. Return
AGAM
Audent Global Asset Management West Hollywood, California $100M AUM 22.83% 1-Year Est. Return
E
Entelevest Coral Gables, Florida $100M AUM
HCM
Hicks Capital Management Columbus, Ohio $100M AUM 14.29% 1-Year Est. Return
AC
Arrow Capital Sydney, Australia $100M AUM 68.52% 1-Year Est. Return
OIS
OneAscent Investment Solutions Birmingham, Alabama $100M AUM 15.97% 1-Year Est. Return

AlphaCentric Advisors's Q3 2022 Portfolio in Review

Q3 2022 is the first quarter with a 13F filing on record for AlphaCentric Advisors, which disclosed 184 positions worth $97.4M. Its ten largest holdings account for 33% of the portfolio.

Its largest position is iShares 1-3 Year Treasury Bond ETF: 157,224 shares worth $12.8M.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, followed by Real Estate and Financials.

  • AlphaCentric Advisors's largest Q3 2022 buy was iShares 1-3 Year Treasury Bond ETF: 157,224 shares worth $12.8M.
  • AlphaCentric Advisors's ten largest holdings make up 33% of its $97.4M portfolio in Q3 2022.
  • AlphaCentric Advisors disclosed 184 positions in Q3 2022, its first 13F filing on record.

Based on AlphaCentric Advisors's 13F filing for Q3 2022, filed 8 Nov 2022.